Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Opening Session Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Oct

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Opening Session Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sezary Syndrome

FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors

Geographic Distribution of Triple-Negative Breast Cancer Clinical Trials

Financial Incentives Increase Smoking Abstinence Among Those Referred for Lung Cancer Screening

Metastasis-Directed Ablation Does Not Improve Survival Outcomes in Oligometastatic Breast Cancer